Jun. 26 at 4:22 AM
$PFE “The
$7.7 Billion Operational CushionTo directly insulate the bottom line and dividend from upcoming Loss of Exclusivity (LOE) pressures like Ibrance and Xeljanz, Pfizer is executing a massive multi-phase cost-realignment program targeting
$7.7 billion in total savings through 2027:
$4.5 Billion in base operational net savings completed by end-of-year 2025.
$1.2 Billion in corporate SG&A reductions driven by digital automation and AI scaling through 2027.
$1.5 Billion stemming from an ongoing global manufacturing optimization initiative.
$500 Million via optimized R&D productivity overhauls.
*Biospace
This aggressive deflation of the company’s internal cost structure artificially preserves operating margins, providing a crucial cash cushion exactly as the Ibrance revenue decline begins in Q2 2027.
Pfizer has aggressively rewritten its capital priority playbook to defend the payout. (AI)
